The global metabolism
drugs market, by Therapy Type (Enzyme Replacement Therapy, Substrate
Reduction Therapy, Small Molecule Drugs, and Others), by Application (Glycogen
Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism Disease, and
Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and
Online Pharmacies), and by Region (North America, Latin America, Europe, Asia
Pacific, the Middle East, and Africa) was valued at US$ 5,765.3 million in
2017, and is projected to exhibit a CAGR of 6.3% over the forecast period (2018
– 2026).
Availability of wide number of
therapies such as small molecule drugs and enzyme replacement therapy,
increasing prevalence of metabolic diseases, and robust pipeline is expected to
fuel growth of the metabolism drugs market. Manufacturers are actively working
on developing new therapies for various metabolic diseases.
For instance, various pipeline
products include NeoGAA GZ402666 (Sanofi) in phase 3, AT-982 in phase 3
(Audentes Therapeutics)), and BMN 701 in phase 2 (BioMarin Pharmaceutical,
Inc.) clinical trial are also expected to create a meteoric growth in this
market during the forecast period. Amicus Therapeutics was granted with orphan
drug designation for its investigational combination drug therapy
ATB200/AT2221, in November 2017. This drug is intended to cure Pompe disease
(acid maltase deficiency or AMD). in March 2018, Shire plc entered into a
preclinical research collaboration with NanoMedSyn— French biotech company—to
develop enzyme replacement treatment for a lysosomal storage disorder based on
NanoMedSyn’s synthetic derivative technology named AMFA.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1955
Lixte Biotechnology Holdings,
Inc., has LB-201/LB-205 in the preclinical stage, JCR Pharmaceuticals Co. Ltd.
filed for JR-051 in Japan in 2017, and has many other products in the pipeline
for treatment of metabolic diseases. Moreover, manufacturers such as Pharming
Group NV and Orphazyme ApS also have products in the pipeline for metabolic
diseases.
Browse 34 Market Data Tables and
43 Figures spread through 167 Pages and in-depth TOC on Metabolism Drugs
Market, by Therapy Type (Enzyme Replacement Therapy, Substrate Reduction
Therapy, Small Molecule Drugs, and Others), by Application (Glycogen Metabolism
Disease, Lipid Metabolism Disease, Amino Acid Metabolism Disease, and Others),
By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific,
the Middle East, and Africa) - Global Forecast to 2026
Partnerships and collaboration
from individual organizations for research and development of effective
therapies is expected to boost growth of the metabolism drugs market. For
instance, in 2014, Shire Plc announced collaboration with ArmaGen to develop
AGT-182 drug for treatment of hunter syndrome. Moreover, in 2017, Research
funded by the National Institute of Neurological Disorders and Stroke (NINDS)
demonstrated that viral-delivered gene therapy can stop the buildup materials
stored in the brain cells and improve memory and learning. High return on
investments, health insurance coverage, and various reimbursement policies for
such costly drugs are influencing pharmaceutical companies to invest in drug
development. For instance, in 2015, Orphan Product Grants Program funded 18 new
grant awards from 92 grant applications and provided funding and support to
around 67 ongoing clinical study projects related to rare disease.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/metabolism-drugs-market-1955
Furthermore, initiatives from the
governments of economies such as Sweden, the Netherlands, and South Korea that
focus on approving guidelines for the reimbursement of individuals undergoing
enzyme replacement therapy (ERT) are also expected to boost growth of the
metabolic drugs market (as enzyme replacement being major therapies in the
market) in the near future.
Key Takeaways of the Metabolism
Drugs Market:
The global metabolism drugs
market is expected to exhibit a CAGR of 3% over the forecast period (2018 –
2026), owing to partnerships and collaboration for drug development by leading
manufacturers such as Shire Plc
Enzyme replacement therapies are
expected to be the driving factor behind growth of the metabolism drugs market
North America is expected to
dominant position in the metabolism drugs market over the forecast period due
to active research and development activities by leading players in the region
Major players operating in the
global metabolism drugs market include Merck & Co., Inc., Novartis AG,
Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi
Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline
Plc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1955
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment